Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Overexpression”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06695845
What this trial is testing

Zanidatamab in Patients With HER2-expressing Tumors

Who this might be right for
Breast CancerGastric CancerEsophageal Cancer+9 more
Jazz Pharmaceuticals 200
Testing effectiveness (Phase 2)Study completedNCT01036087
What this trial is testing

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 47
Testing effectiveness (Phase 2)WithdrawnNCT01427244
What this trial is testing

Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Who this might be right for
Paget's Disease of the Vulva
Yale University
Testing effectiveness (Phase 2)Ended earlyNCT00756470
What this trial is testing

Phase II Neoadjuvant in Inflammatory Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 15
Early research (Phase 1)Looking for participantsNCT07361562
What this trial is testing

A Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor, AdultERBB2 Altered Breast CancerERBB2 Gene Amplification+3 more
Cogent Biosciences, Inc. 100
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Large-scale testing (Phase 3)UnknownNCT04714190
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 351
Testing effectiveness (Phase 2)Study completedNCT02748213
What this trial is testing

Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 225
Testing effectiveness (Phase 2)Study completedNCT00429104
What this trial is testing

Herceptin and GM-CSF for Metastatic Breast Cancer

Who this might be right for
Breast Cancer
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT01828736
What this trial is testing

Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Recurrent Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie 61
Not applicableEnded earlyNCT00358098
What this trial is testing

Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AHS Cancer Control Alberta 51
Testing effectiveness (Phase 2)Ended earlyNCT02013765
What this trial is testing

Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

Who this might be right for
Urinary Tract Cancer
Hoffmann-La Roche 5
Early research (Phase 1)Ended earlyNCT01199367
What this trial is testing

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Kyowa Kirin Co., Ltd. 11
Testing effectiveness (Phase 2)Looking for participantsNCT06560528
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital 40
Early research (Phase 1)Ended earlyNCT04209465
What this trial is testing

BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Who this might be right for
Solid Tumor
Black Diamond Therapeutics, Inc. 91
Testing effectiveness (Phase 2)UnknownNCT06227325
What this trial is testing

Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

Who this might be right for
Gastric Cancer
Henan Cancer Hospital 27
Testing effectiveness (Phase 2)WithdrawnNCT00022230
What this trial is testing

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Who this might be right for
Breast Cancer
Roger Williams Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT05315700
What this trial is testing

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Who this might be right for
Solid Tumors
ORIC Pharmaceuticals 350
Early research (Phase 1)Study completedNCT05904730
What this trial is testing

Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations

Who this might be right for
Breast CancerOvarian CancerBreast Neoplasms+5 more
Lynkcell Europe 10
Large-scale testing (Phase 3)Active Not RecruitingNCT05911295
What this trial is testing

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 412
Next Page